September 30, 2021 5:45pm

September ended with 1 holiday, 10 positive and 10 negative closes of my 35 covered

The Biostage (BSTG) Chronicles:  What happened to the “pump/promote” … Thursday closed down -$0.02 with 6,030 shares traded – being defeated

Pre-open indication results: 4 Hits and 3 MISS

Who else is tracking a broad representative index of cell and gene therapy equities – the facts are supported by real numbers?

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

End of Month closing session numbers ...

The Dow closed DOWN -546.80 points (-1.59%); the S&P closed DOWN -51.92 points (-1.19%) while the Nasdaq closed DOWN -63.86 points (- 0.44%)

 

Henry’omics:

Indexes moved lower on Thursday closing out a rough month.

The closing moves put the Dow down more than -3% for September, while the S&P 500 was down -4% and the Nasdaq by more than -4%.

Investors were also keeping an eye on Washington as Senate was poised to pass a bill that would fun the government through early December. The deal would still need to pass the House.

 

Economic Data Docket: initial jobless claims for the prior week came in at 362,000. Economists were expecting a print of 335,000.

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …

  • Thursday opened positive at 22/9, 3 flats and 1 acquired, flipped stayed positive at the mid-day at 20/12, 2 flats and 1 acquired, ending with a negative close of 16/17, 1 flat and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “a finger in sentiment’s dike could stem the low volume downside flow. Month and quarter’s end has its liabilities” … https://www.regmedinvestors.com/articles/12118

 

Pre-open indication results: 4 Hits: <Biostage (BSTG -$0.02), bluebird bio (BLUE +$0.13), CRISP Therapeutics (CRSP +$1.73), Global Blood Therapeutics (GBT -$0.37)> and 3 MISS < Editas Medicine (EDIT -$1.42), Ionis Pharmaceuticals (IONS -$0.04), Intellia Therapeutics (NTLA -$3.42)

 

The Biostage (BSTG) Chronicles: “wrongful death law suit, insurance claim denied” … https://www.regmedinvestors.com/articles/12110  - negligence? <read newest version

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

  • Net Income: 3 and Net losses: 24

 

Key Metric - volume:

  • Sector volume was LOW with 3 of the 16-upside having higher than the 3-month average volume with INCREASED volume of 6 of 17-downside having higher than the 3-month average volume;

 

The Biostage (BSTG) Chronicles: wrongful death law suit, insurance claim denied” … negligence? https://www.regmedinvestors.com/articles/12110

  • The “pump/promote” is back …

Thursday closed down -$0.02 with 6,030 shares traded following Wednesday close down -$0.72 with 1,273 shares traded after Tuesday closed up +$0.48 at $3.74 with 1,236 shares traded, Monday also closed flat with 135 shares traded, Friday closed flat with 62 shares traded, Thursday closed up +$0.06 with 839 shares traded and last Wednesday closed down -$0.45 with 3,833 shares traded.

  • WERE BSTG’s Q2 8-K and 10-Q filings AUDITED or UNAUDITED for investors?
  • Will legal fees to defend the terminal death suit going to bankrupt the company now, that costs will not be covered by insurance?
  • The largest issue was NOT providing the documents to the other attorneys as a sanction was put-on and then removed?
  • Should the D&O, company and office and board covered insurances <which were very high> about to jump even higher – who is paying – investors to protect malfeasant?

Hong Yu - president, Shunfu Hu and Linghui Meng V.P.'s of what - NEGLIGENCE ... they SHOULD/MUST RESIGN, where is William (BILL) Fodor PhD - CSO, the overseer of a non-happening clinical trial after 1 year and 6 months of approval!

 

There are clear winners and losers

Jumping with share pricing momentum (10 of 16):

  • Alnylam Pharmaceuticals (ALNY +$11.36 after Wednesday’s +$0.37, Tuesday’s -$16.77 and Monday’s +$6.45)
  • Ultragenyx (RARE +$4.07 after Wednesday’s -$0.88, Tuesday’s -$1.66 and Monday’s -$6.45),
  • CRISPR Therapeutics (CRSP +$1.73 after Wednesday’s -$1.95, Tuesday’s -$5.11 and Monday’s +$0.83),
  • Vericel (VCEL +$0.60 after Wednesday’s +$0.05)
  • uniQure NV (QURE +$0.50 after Wednesday’s -$0.81)
  • BioLife Solutions (BLFS +$0.29)
  • Chinook Therapeutics (KDNY +$0.27 after Wednesday’s +$0.03)
  • Sage Therapeutics (SAGE +$0.16 after Wednesday’s -$0.84, Tuesday’s -$1.57 and Monday’s +$1.44),
  • bluebird bio (BLUE +$0.13)
  • Brainstorm Cell Therapeutics (BCLI +$0.12)

Hammered in today’s market (10 of 17):

  • Intellia Therapeutics (NTLA -$3.41 after Wednesday’s -$8.17, Tuesday’-$1.85 and Monday’s -$1.56)
  • Editas Medicine (EDIT -$1.42 after Wednesday’s -$9.95, Tuesday’s -$5.39 and Monday’s -$0.87)
  • AxoGen (AXGN -$0.53 after Wednesday’s +$0.34)
  • Fate Therapeutics (FATE -$0.53 after Wednesday’s -$0.99, Tuesday’s -$3.57 and Monday’s -$0.49)
  • ReNeuron (RENE.L -$0.50 after Wednesday’s +$1.50, Tuesday’s -$1.50 and Monday’s -$1.00),
  • Global Blood Therapeutics (GBT -$0.32 after Wednesday’s -$0.75, Tuesday’s +$0.33 and Monday’s +$0.65),
  • Regenxbio (RGNX -$0.18 after Wednesday’s -$1.39)
  • MiMedx (MDXG -$0.18 after Wednesday’s +$0.17)
  • Voyager therapeutics (VYGR -$0.12)
  • Sangamo Therapeutics (SGMO -$0.11)

Closing Flat:

  • 1 – Pluristem (PSTI) and 1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday the IBB closed up +0.17% and XBI closed up +0.06%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was up +0.58 points or +2.57% at 23.13

 

 

September, the third month of Q3/21:

Thursday closed negative with 16 advancers, 17 decliners, 1 flat and 1 acquired

Wednesday closed negative with 6 advancers, 28 decliners and 1 acquired

Tuesday closed negative with 3 advancers, 31 decliners and 1 acquired

Monday (9/27) closed positive with 18 advancer, 15 decliners, 1 flat and 1 acquired

Friday closed negative with 4 advancers, 28 decliners, 2 flats and 1 acquired

Thursday closed positive with 29 advancers, 5 decliners and 1 acquired

Wednesday closed positive with 18 advancers, 14 decliners, 2 flat and 1 acquired

Tuesday closed positive with 22 advancers, 9 decliners, 2 flats and 1 acquired

Monday (9/20) closed negative with 1 advancer, 33 decliners and 1 acquired

Friday closed positive with 28 advancers, 6 decliners and 1 acquired

Thursday closed positive with 16 advancers, 13 decliners, 5 flat and 1 acquired

Wednesday closed positive with 18 advancers, 14 decliners, 2 flat and 1 acquired

Tuesday closed negative with 5 advancers, 29 decliners and 1 acquired

Friday closed negative with 7 advancers, 26 decliners, 1 flat and 1 acquired

Thursday closed positive with 20 advancers, 13 decliners, 1 flat and 1 acquired

Wednesday closed negative with 7 advancers, 27 decliners and 1 acquired

Tuesday closed negative with 10 advancers, 22 decliners, 2 flats and 1 acquired

Monday was a holiday

Friday closed negative with 8 advancers, 26 decliners and 1 acquired

Thursday closed positive with 27 advancers, 5 decliners, 2 flat and 1 acquired

Wednesday closed positive with 20 advancers, 13 decliners, 1 flat and 1 acquired

 

 

The BOTTOM LINE: Rising yields, fueled by concerns over inflation and the Fed’s signals that it will soon begin winding down its pandemic-era asset purchases, are seen as a negative for stocks because they make far-off future profits less attractive to investors.

We are now headed into October which has a reputation for some violent sell-offs but overall is typically the start of a better seasonal performance for stocks.

Many of us, investors were left wondering whether the declines were the start of a broader sector pullback or just another blip.

Investors were still mulling implications on-going Washington, D.C. political antics, inflation worries, bond yields, infrastructure arguments, questions of drug pricing and patterns while military patterns of behavior re the debacle of the Afghanistan withdrawal i.e., surrender “bites” and hard!

Sentiment has been capricious and languishing as the sector bounded to the downside.

The stem, cell and gene therapy sector is still seen as vulnerable to extreme moves in either direction, overbought and oversold categories as risk stimulates the susceptibility!

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.